Aurora Cannabis (ACB)
(Delayed Data from NSDQ)
$5.98 USD
+0.44 (7.94%)
Updated Nov 4, 2024 03:59 PM ET
After-Market: $5.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.98 USD
+0.44 (7.94%)
Updated Nov 4, 2024 03:59 PM ET
After-Market: $5.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Zacks News
Livongo Health (LVGO) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Livongo Health (LVGO) first-quarter performance to reflect growth in core Livongo for Diabetes solution.
What's in Store for AmerisourceBergen's (ABC) Q2 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter results likely to reflect solid performance at Pharmaceutical Distribution.
What's in Store for Becton, Dickinson's (BDX) Q2 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) fiscal second-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.
OPKO Health (OPK) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
OPKO Health's (OPK) first-quarter performance is likely to reflect solid performance from Products and RAYALDEE.
Genetic Testing Likely to Drive Invitae's (NVTA) Q1 Earnings
by Zacks Equity Research
Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q1.
What's in the Cards for DaVita (DVA)This Earnings Season?
by Zacks Equity Research
DaVita (DVA) is expected to have gained from Kidney Care segment in Q1.
What's in Store for Varian Medical (VAR) in Q2 Earnings?
by Zacks Equity Research
Varian's (VAR) solid Oncology platform is expected to have driven fiscal second-quarter performance.
PerkinElmer (PKI) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results likely to reflect top-line growth and robust performance at Diagnostics segment. However, forex is likely to have remained a woe.
T2 Biosystems (TTOO) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
T2 Biosystems' (TTOO) first-quarter performance is likely to reflect growth in product revenues.
Aurora Cannabis Inc. (ACB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed the most recent trading day at $0.75, moving -1.68% from the previous trading session.
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) first-quarter performance to reflect focus on product innovation and R&D.
Humana (HUM) Gears up for Earnings in Q1: What to Expect
by Zacks Equity Research
Humana's (HUM) Q1 earnings results are likely to reflect growth in revenues, which in turn, are expected to have been driven by its Medicaid and Medicare businesses.
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed at $0.72 in the latest trading session, marking a -0.29% move from the prior day.
5 Recession-Proof Stocks to Buy Amid Coronavirus-Led Job Crisis
by Zacks Equity Research
Five recession-proof stocks that are poised to return well on investment amid this coronavirus-led job crisis.
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $0.75, marking a -1.42% move from the previous day.
Here's Why You Should Hold on to Luminex (LMNX) Stock Now
by Zacks Equity Research
Luminex (LMNX) continues to benefit from robust product portfolio, solid molecular diagnostics and ARIES platforms.
BD (BDX) Receives EUA for New Coronavirus Detection Test
by Zacks Equity Research
Becton, Dickinson (BDX) receives EUA from the FDA for another molecular diagnostic test for COVID-19, which can return results in two to three hours.
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed the most recent trading day at $0.80, moving -1.27% from the previous trading session.
Aurora Cannabis (ACB): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Aurora Cannabis (ACB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $0.91, marking a +1.97% move from the previous day.
Implied Volatility Surging for Aurora Cannabis (ACB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aurora Cannabis (ACB) stock based on the movements in the options market lately.
Here's How Coronavirus Can Impact Cannabis Industry
by Zacks Equity Research
Marijuana should be avoided during the pandemic as users share marijuana joints, which may increase the spread of the virus.
What Do Canopy Earnings Say About Cannabis ETFs?
by Sanghamitra Saha
Solid earnings drive Canopy Growth stock and boost the industry as a result. Is it right time to buy marijuana ETFs?
New Strong Sell Stocks for February 14th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Implied Volatility Surging for Aurora Cannabis (ACB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aurora Cannabis (ACB) stock based on the movements in the options market lately.